US20040197426A1 - Use of phyllanthus constituents for treating or preventing infections caused by hepatit - Google Patents

Use of phyllanthus constituents for treating or preventing infections caused by hepatit Download PDF

Info

Publication number
US20040197426A1
US20040197426A1 US10/476,059 US47605904A US2004197426A1 US 20040197426 A1 US20040197426 A1 US 20040197426A1 US 47605904 A US47605904 A US 47605904A US 2004197426 A1 US2004197426 A1 US 2004197426A1
Authority
US
United States
Prior art keywords
substances
phyllanthus
hepatitis
virus
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/476,059
Other languages
English (en)
Inventor
Michael Ott
Michael Manns
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of US20040197426A1 publication Critical patent/US20040197426A1/en
Priority to US11/563,540 priority Critical patent/US7829124B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the invention relates to the use of one or more Phyllanthus component(s) or substances or mixtures of substances obtained therefrom for the prevention or treatment of infectious diseases caused by a hepatitis B virus which is resistant to nucleoside analogues or in the development or progression of which a hepatitis B virus resistant to nucleoside analogues plays a role.
  • the invention relates to the use of one or more Phyllanthus component(s) or substances or mixture of substances obtained therefrom for the production of a pharmaceutical composition for the prevention or treatment of infectious diseases caused by a hepatitis B virus which is resistant to nucleoside analogues or in the development or progression of which a hepatitis B virus resistant to nucleoside analogues plays a role. Furthermore, the invention relates to the use of one or more Phyllanthus component(s) or substances or mixtures of substances obtained therefrom for the inhibition of the growth of a hepatitis B virus which is resistant to nucleoside analogues.
  • the invention relates to methods for the prevention or treatment of infectious diseases in a mammal caused by a hepatitis B virus which is resistant to nucleoside analogues or in the development or progression of which a hepatitis B virus resistant to nucleoside analogues plays a role, wherein one or more Phyllanthus component(s) or substances or mixtures of substances obtained therefrom are administered to the mammal.
  • the invention relates to methods for the inhibition of the growth of a hepatitis B virus resistant to nucleoside analogues, wherein one or more Phyllanthus component(s) or substances or mixtures of substances obtained therefrom are contacted with the viruses.
  • the nucleoside analogues are selected from the group consisting of Lamivudine and Famciclovir.
  • the plant genus Phyllanthus belongs to the subfamily of the Phyllanthoideae which belongs to the family of the Euphorbiaceae.
  • the genus Phyllanthus comprises about 700 species in total which have their origin in the tropical and subtropical areas in Australia, China, the Philippines, Thailand, Indonesia, Burma, India, East and West Africa as well as North America, Mexico, Cuba, the Caribbean and Venezuela. Representatives of the genus Phyllanthus are found in the Northern temperate zones very rarely only.
  • Phyllanthus Due to the heterogeneity of the genus Phyllanthus, only few genus-specific features are known. The majority of the representatives of the genus Phyllanthus are monoecious or dioecious herbs, bushes or trees with varied growth (habitus) exhibiting stalks or branches differentiated into two to three different types. Thus, Phyllanthus has both straight long shoots of unlimited growth and short shoots and horizontal leafy or blossomy short shoots of limited growth. Often, two different types of leaves are observed, wherein the non-foliage leaves are found on the upward and short shoots and the foliage leaves are found on the horizontal shoots.
  • the blossoms are small and axillar, whereby the female blossoms including their flower stalks and sepals are more robust than the male blossoms. Since there are no clear generic boundaries between the different genuses, and some Phyllanthus species can be categorised into various genuses according to point of view, it is very difficult to get a clear picture of sufficient genus-specific ingredients and groups of ingredients. The only uniform point is the lack of latex which is considered a family feature of the subfamily Phyllanthoideae. Some characteristic groups of substances, however, are more or less widespread in Phyllanthus. In this context, alkaloids, in particular the alkaloids of the prevalent securinine type, are to mention, which only occur in some species.
  • Alkaloids were detected, for example, in all the parts of the plants of Phyllanthus niruri . Furthermore, compounds belonging to the cyanogenic glycosides occur occasionally. They belong to the tyrosine-derived descendants of the class. A typical representative thereof is taxiphyllin and 2-hydroxy-2-(4-hydroxyphenyl)acetonitrile in the leaves of Phyllanthus gasstroemii . Tanning agents, in particular tannins and ellagitannins as well as their precursors preferably occur on wooden species in the tropics. In this context, the main representatives are Phyllanthus emblica with Phyllemblin (ethyl gallat) in the fruit.
  • Phyllanthusine an ellagitannin derivative in the herb of Phyllanthus amarus
  • a further big group of ingredients relates to lignanes, while in the herb of Phyllanthus amarus and in all the parts of Phyllanthus niruri , lignanes such as, for example, Phyllanthin and cycloliganes or tetraliganes such as, for example, Hypophyllanthin occur.
  • sesquiterpenes in Phyllanthus acuminatus are described which chemically belong to the epoxides of tricyclic sesquiterpenes with spiran structure and partly ester-like-bound bioses.
  • hydrolysable tanning agents of the genus Phyllanthus inhibits important eukaryotic protein kinases such as the cAMP-dependent protein kinase of the rat liver, the CA 2+ -dependent protein kinase of the wheat embryo, the CA 2+ - and phopholipid-dependent protein kinase C (PKC) of the rat brain, whereas the tanning agents amariin, geraniin and the phenazine-derivative of the geraniin each are most effective.
  • important eukaryotic protein kinases such as the cAMP-dependent protein kinase of the rat liver, the CA 2+ -dependent protein kinase of the wheat embryo, the CA 2+ - and phopholipid-dependent protein kinase C (PKC) of the rat brain
  • PKC phopholipid-dependent protein kinase C
  • HBV transfer of HBV takes place by blood or body fluids, whereby the human serves as virus reservoir; however, an experimental transfer to chimpanzees is possible.
  • concentration of infectious particles in acutely or chronically infected patients can reach a level of 10 9 /ml blood.
  • the virus can be passed on to the child by the infected pregnant mother rarely before, but mostly during birth. This is the case mainly in the highly endemic areas of East Asia, Central and West Africa, where about 20-80% of the population is infected with HBV. At the moment, it is assumed that about 350 million people are chronically infected with HBV. In Germany, endemic virus spreading is only sporadic; only about 0.5% of the population are HbsAg-positive and about 5% have antibodies.
  • the target organ of HBV is the liver.
  • acute hepatitis may occur.
  • the infection shows no symptoms
  • the patients develop an inflammation of the liver.
  • the main symptom of an acute hepatitis is the development of a jaundice (icterus) and an enlargement of the liver at the same time.
  • aplastic anaemia and exanthems are important for healing of the hepatitis.
  • healing of the hepatitis is achieved after 4 to 6 weeks.
  • the inflammation of the liver can turn into a chronic state.
  • About 5-10% of all HBV infections in adults take this chronic course.
  • HCC is more likely to occur in people with a chronically persisting HBV infection, whereas the likelihood to get an HCC increases with prolonged infection.
  • One reason for the development of HCC is the integration of the viral DNA into the host genome. In this context, the opening of the circular DNA takes place in the region of the origin replication so that no virus, but the HBs- and X-gene still can be expressed, wherein the X-protein, in particular, is suspected to have transforming characteristics. Furthermore, the unspecific integration of the genome itself can lead to cell transformation. HBV has a synergistic effect with aflatoxines during the development of an HCC.
  • the problem underlying the present invention is to provide means and ways to treat infections caused by hepatitis B viruses resistant to nucleoside analogues and diseases based thereon and to prevent their onset by prophylaxis. This task has been solved by the embodiments characterised in the claims.
  • the invention relates to the use of one or more Phyllanthus component(s) or substances or mixtures of substances obtained therefrom for the prevention or treatment of infectious diseases caused by a hepatitis B virus which is resistant to nucleoside analogues or in the development or progression of which a hepatitis B virus resistant to nucleoside analogues plays a role.
  • the term “Phyllanthus component(s)” relates to all the constituents of the whole plants such as e.g. leaves, bark, blossoms, seeds, fruits, stalks, branches, stems, roots and wood, as well as parts thereof such as e.g. leaf or roots apexes. These Phyllanthus constituents can exhibit the same, similar or non-related ingredients. Therefore, different Phyllanthus constituents can be used individually or together and different Phyllanthus constituents of different Phyllanthus species can be used individually or together. “Several” Phyllanthus constituents relates to the all the Phyllanthus constituents, for example, in form of whole plants or extracts thereof. The Phyllanthus constituents can be used after pre-treatment or without pre-treatment. Pre-treatment could, for example, comprise procedures such as the drying of leaves.
  • “Substances or mixtures of substances” which can be obtained from Phyllanthus constituents mainly relate to active agents. These can be used in pure or impure form. These active agents can be used individually or in combination as active agents or mixture of active agents. In this context, different active agents can be present in different Phyllanthus constituents or in the same Phyllanthus constituents. Mixtures of active agents can be obtained from the same Phyllanthus component or from different Phyllanthus constituents.
  • obtaining of the active agents from the different Phyllanthus constituents can take place individually, to start with, wherein, subsequently, the individual active agents are united to form a mixture of active agents, or, at the same time, a mixture of active agents can be obtained from Phyllanthus constituents united earlier.
  • Substances or mixtures of substances according to the invention can consist of the same or of different representatives of a class of chemical compounds. These chemical compounds can be used in natural form, i.e. unmodified by the obtaining process or modified by the obtaining process.
  • the chemical compounds can, for example, be cyclic or branched or non-branched polar or non-polar hydrocarbons, lipids, lipid derivatives, nucleic acids, nucleotides, nucleotide derivatives, nucleosides, nucleoside derivatives, polypeptides, peptides, amino acids or modified amino acids.
  • derivatives relate to all the compounds that can be derived from the compounds mentioned and can be achieved by chemical modification. For example, such derivatives can be formed by substitution, addition, esterification, saponification or condensation reactions.
  • prevention relates to the use of Phyllanthus constituents or substances or mixtures of substances obtained therefrom as a phrophylaxis for the prevention of the infection with hepatitis B virus resistant to nucleoside analogues or for the reduction of the virus load. Furthermore, according to the invention, this relates to avoiding the breakout of the disease or achieving a less severe breakout of the disease.
  • the Phyllanthus constituents or substances or mixtures of substances used for prevention can be different from or identical to the Phyllanthus constituents or substances or mixtures of substances used for treatment. The use for prevention can take place in a different or the same dose and by a different or the same application as in the use for treatment.
  • the dose of Phyllanthus constituents or substances or mixtures of substances used for prevention should, however, essentially offer sufficient protection against infectious diseases caused by hepatitis B viruses which are resistant to nucleoside analogues or in the development or progression of which these viruses play a role. At the same time, the dose used for prevention should not have a harming effect on the organism.
  • Phyllanthus constituents or substances or mixtures of substances obtained therefrom can be used in a similar way as described for the prevention.
  • the dose used for the treatment can fight both the cause of the infectious diseases, i.e. the viruses and their growth in the organism, and the symptoms of the infectious diseases.
  • compositions for the treatment, the constituents and substances or mixtures of substances are formulated as pharmaceutical compositions, medicinal products or medicinal adjuvant.
  • pharmaceutical compositions see the description below.
  • Infectious diseases are in particular characterised by an immune response being triggered in the organism, caused by a pathogen.
  • the objective of this immune response is to fight the pathogen.
  • severe damage to the cells and the tissues of the organism concerned can be caused which, in this case, can be caused by the immune system itself.
  • the pathogen itself may cause damage, since, for example in infected cells, metabolic processes or differentiation programmes can be deleted which have a damaging effect on the organism.
  • causes and symptoms of the infectious diseases can relate to identical cells or tissue but also different ones.
  • a modified liver metabolism could lead to a modification of the composition of the proteins contained in the blood, in particular the enzymes, which could, again, lead to damage of other organs, e.g. the kidney.
  • the use of Phyllanthus component(s) or substances or mixtures of substances obtained therefrom according to the invention not only relates to the prevention or treatment of causes of infectious diseases, such as e.g. an infection by viruses, but also the prevention or treatment of symptoms occurring secondarily which are due to the presence of the pathogen in the organism.
  • pathogen relates to a hepatitis B virus which is resistant to nucleoside analogues.
  • the hepatitis B virus in total comprises eight different subtypes characterised in that they all cause threatening diseases.
  • hepatitis is of particular importance; it leads to modifications of the morphology and, at the same time, of the function of the liver, which are life-threatening for the organism.
  • prophylactic measures such as the use of Phyllanthus constituents or substances or mixtures of substances obtained therefrom according to the invention are shown for the prevention.
  • the Phyllanthus constituents or substances or mixtures of substances obtained therefrom according to the invention can alleviate the infectious disease caused by hepatitis B viruses which are resistant to nucleoside analogues, in particular by inhibition of the growth of the viruses in the cells and tissues affected. This can take place, for example, by the inhibition of individual or different enzymes underlying the cellular changes in connection with the infectious disease.
  • the Phyllanthus constituents or substances or mixtures of substances obtained therefrom used according to the invention can, additionally for example as immune modulators, positively influence a prevention or treatment of infectious diseases caused by viruses of the family of the Flaviviridae.
  • development or progression relates to the fact that the hepatitis B viruses which are resistant to nucleoside analogues can as pathogens either be the cause and, therefore, play a part either alone or in combination with other pathogens or, however, can promote the progession of an existing infectious disease either alone or in combination with other pathogens.
  • the use according to the invention shows surprising and unexpected positive effects during the prevention or treatment of infectious diseases which are due to infections by hepatitis B viruses which are resistant to nucleoside analogues.
  • nucleoside analogues such as e.g. Lamivudine and Famciclovir, a successful treatment by Phyllanthus constituents or substances or mixtures of substances obtained therefrom was not to be expected.
  • the invention relates to the use of one or more Phyllanthus component(s) or substances or mixture of substances obtained therefrom for the production of a pharmaceutical composition for the prevention or treatment of infectious diseases caused by a hepatitis B virus which is resistant to nucleoside analogues or in the development or progression of which the hepatitis B virus resistant to nucleoside analogues plays a role.
  • compositions are substances and preparations of substances which are meant to alleviate, prevent or recognise diseases, ailments, damage to the body or disease-related discomforts by means of application on or in the human body.
  • medicinal products are substances or preparations of substances used alone or in combination with each other or other subjects meant by the manufacturer to serve for the application for humans by means of their functions with the purpose of recognising, preventing, monitoring, treating or alleviating diseases and whose main effect in or on the human body, according to its objective, is achieved neither by agents with a pharmacological or immunological effect nor by metabolisms whose effectiveness, however, can be supported by such agents.
  • medicinal adjuvants are substances which are used for the production (as active ingredients) of pharmaceutical compositions.
  • suitable pharmaceutically acceptable carriers comprise phosphate-buffered sodium chloride solutions, water, emulsions such as e.g. oil/water emulsions, various types of detergents, sterile solutions, and so on.
  • Pharmaceutical compositions comprising such carriers can be formulated by means of conventional methods known. These pharmaceutical compositions can be administered to an individual in an appropriate dose, e.g. in a range of 1 ⁇ g to 100 mg per day and patient. The administration can take place in various ways, e.g. in an intravenous, intraperitoneal, a subcutane, intramuscular, local or intradermal way. The type of dosage is determined by the doctor in charge according to the clinical factors.
  • the type of dosage depends on various factors such as e.g. the size, the body surface, the age, the sex or the general health of a patient, but also on the specific preparation which is administered, the duration and kind of application and on other drugs possibly being administered at the same time.
  • the infectious disease is yellow fever, cirrhosis or hepatocellular carcinoma.
  • the invention relates to the use of one or more Phyllanthus component(s) or substances or mixtures of substances obtained therefrom for the inhibition of amplification of the hepatitis B virus which is resistant to nucleoside analogues.
  • “Inhibition of amplification of hepatitis B viruses which are resistant to nucleoside analogues” relates to the fact that the replication of the viruses in the affected host cell or virus budding from an infected host cell or both is prevented. Moreover, the infection of further host cells of the viruses could be prevented and amplification of the viruses could be achieved by means of blocking of the target cells (host cells). During the inhibition of the formation of new viruses in an infected host cell, enzymes which play a role in the formation of new viruses, above all, can be inhibited.
  • the inhibition of amplification by inhibition of virus budding from an infected host cell could be caused, in particular, by the inhibition of the viral and/or cellular proteins essential for the budding process.
  • the inhibition of amplification of the blockage of further host cells could be achieved by inhibition of the mechanisms which play a role in the recognition of host cells and viruses or which play a role in the uptake of the virus into the host cell or by inhibition.
  • the inhibition takes place ex vivo or in vitro.
  • This embodiment is of interest, in particular, for the further development of active agents according to the invention, the analysis of new active agents or for the quality control thereof.
  • the inhibition can be carried out outside the organism, too, in isolated cells or tissues, e.g. in cell culture.
  • in in vitro systems e.g. in cell cultures, it can be analysed which constituents of Phyllanthus exhibits the most advantageous characteristics.
  • an optimising of the substances or mixtures of substances can be carried out on the basis of in vitro test systems.
  • Phyllanthus constituents are divided into groups of active agents or in single constituents according to common chemical/physical methods and the single constituents in such test systems are tested for inhibition of virus growth.
  • the one or more Phyllanthus component(s) or substances or mixtures of substances obtained therefrom are derived from Phyllanthus amarus, Phyllanthus niruri, Phyllanthus emblica, Phyllanthus urinaria, Phyllanthus acidus, Phyllanthus acuminatus and Phyllanthus reticulatus or from several of these Phyllanthus species.
  • the hepatitis B virus which is resistant to nucleoside analogues exhibits one or more mutations in the reverse transcriptase.
  • the term “one or more mutations” means one or more mutations in the nucleic acid sequences of the virus or in the amino acid sequences of polypeptides derived therefrom.
  • nucleic acids can comprise particularly DNA or RNA.
  • the mutations present in the nucleic acid sequence can lead to the substitution of an amino acid in the amino acid sequence of the viral polypeptides, which can be responsible for the change of the function of viral polypeptides.
  • the function of enzymes of the virus can in particular be influenced.
  • the enzymes created in this connection can be responsible for the resistances of hepatitis B virus strains formed against common active agents as e.g. Lamivudine or Famciclovir.
  • mutations at the nucleic acid level can, of course, also interfere with the efficiency of the transcription and/or the efficiency of the translation of various parts of the viral genome and can thus influence the intracellular concentration of the viral enzymes in the affected host cell in a positive or negative way.
  • Reverse transcriptase means an enzyme with the property of a DNA or RNA dependent DNA polymerase. Both retroviruses and hepatitis viruses have such a reverse transcriptase. In the case of the hepatitis B virus, the reverse transcriptase encoded by the viral genome is a multifunctional enzyme. The reverse transcriptase can be divided into four domains, on the one hand, the functional domains of the polymerase and RNase H activity and, on the other hand, the structural domains. The reactions catalysed by the reverse transcriptase occur analogously to the normal DNA polymerase reactions, and as is the case with the other DNA polymerases, a primer is also necessary here.
  • the RNA template is normally a single strand and a single complementary DNA strand is synthesised so that an RNA-DNA hybrid is formed.
  • the cDNA copy of the mRNA can be transferred into a double stranded DNA if the original RNA template is removed with RNaseH or by alkaline hydrolysis.
  • the single stranded DNA product serves as its own primer (and as template) for the synthesis of the complementary second DNA strand.
  • This reaction can be catalysed either by the DNA polymerase I or by the reverse transcriptase itself.
  • a short hairpin loop is formed near the 3′-hydroxyl end of the first strand which means that a primer is available.
  • the complete double strand still carries at one end the hairpin loop, which is eventually split off by a single-strand specific nuclease, so that two completely complementary DNA single strands (a cDNA double strand) are formed.
  • the one or more mutations comprise a substitution of an isoleucine by a methionine at the position 552 or at a corresponding position.
  • a “corresponding position” to position 552 is to be understood as a substitution of an isoleucine by a methionine in the amino acid motif YMDD, wherein the YMDD amino acid motif does not necessarily have to be at positions 551 to 554, but e.g. it can be moved by possible deletions or additions of nucleotides on the nucleic acid level.
  • the prevention or treatment comprises the inhibition of one or more viral enzymes.
  • the inhibition of one or more vial enzymes means that the function of these enzymes is either directly or indirectly influenced in a negative way.
  • a direct inhibition can e.g. (the inventors not wanting to be bound to a scientific therapy here or in the other embodiments) be the case by interaction of one or more inhibitory substances contained in the Phyllanthus constituents or in substances or in mixtures of substances obtained therefrom according to the invention with one or more enzymes or an indirect inhibition by interaction of these inhibitors with factors which are either necessary for the expression, the translation or the processing of these enzymes.
  • viral enzymes as e.g. helicases, polymerases, reverse transcriptases or proteases.
  • a direct inhibition of these enzymes could e.g.
  • cellular enzymes too, which e.g. contribute to the expression, translation or post-translational modification of the viral enzymes and thus direct their function could be either impaired or additionally impaired by these inhibitors.
  • the inhibition of one or more viral enzymes according to the invention the proliferation and/or the infectious disease resulting from the attack by the virus or its development or progression is alleviated.
  • the inhibition comprises the inhibition of the processing of one or more viral enzymes.
  • processing means that at an enzyme which is at first inactive is activated by post-translational modifications, e.g. proteolytic cleavage, phosphorylation or glycosylation.
  • post-translational modifications e.g. proteolytic cleavage, phosphorylation or glycosylation.
  • the Phyllanthus constituents or the substances or mixture of substances obtained therefrom according to the invention which are used for the inhibition of the processing can, in this context, inhibit either one or more viral enzymes at the same time. This can be carried out either by inhibition of the same or by inhibition of different processing steps which are necessary for the activation of the enzyme.
  • an enzyme is the reverse transcriptase.
  • reverse transcriptase is to be understood in accordance with the definition given above.
  • the reverse transcriptase has a substitution of an isoleucine by a methionine at position 552 or at a corresponding position.
  • nucleoside analogues are selected from the group consisting of Lamivudine and Famciclovir.
  • the Phyllanthus constituents comprise the herb drug, the leaves, the bark, the blossoms, the seed, the fruits, the stalks, the branches, the stem, the root and the wood.
  • the substances or mixtures of substances are selected from the group consisting of alkaloids, tanning agents, lignans, sesquiterpenes, triterpenes and cyanogenic glycosides.
  • Alkaloids are a group of substances which is outstanding in that it contains one or more nitrogen atoms, mostly has a heterocycle and is in general bound to a plant acid in a salt-like manner. From a chemical point of view, protoalkaloids, among these are also biogenic amines as precursors of alkaloids, and pseudoalkaloids can be distinguished. Derivatives of certain acid families as e.g. precursors can be understood by alkaloids in a narrower sense. Another important class of substances among the substances or mixtures of substances which can be recovered are the so-called cyanogenic glycosides.
  • Glycosides comprise constituents which are created, with an efflux of water, by the reaction of the acetalic hydroxy group at the C1 atom of a sugar with OH groups of alcohols and phenols or other sugars, NH-groups of amines or SH groups of isothiocyanate.
  • Typical representatives of cyanogenic glycosides are taxiphyllin and 2-hydroxy-2-(4-hydroxyphenyl)acetonitrile.
  • Tanning agents are particularly characterised by phenolic hydroxy groups.
  • the group of terpenes which comprises the sesquiterpenes and the triterpenes consists of unsaturated hydrocarbons which consists of basic isoprene units and are present as polymers.
  • the substances and mixtures of substances of the invention can be present as pure substance or they can have contaminations. Moreover, mixtures of substances can consist of different members of this group and, furthermore, they can contain other additional substances or mixtures of substances.
  • aqueous non-polar, branched or linear chain hydrocarbons are used together with n-hexane for the extraction of the substance of the mixture of substances.
  • Non-polar, branched or linear chain hydrocarbons particularly serve as solvent during the extraction of substances or mixtures of substances from Phyllanthus constituents, wherein the non-polar solvent are in particular characterised in that they do not contain polar groups.
  • these are e.g. benzole or saturated hydrocarbons.
  • the hydrocarbons of the invention should in particular be characterised by a framework of hydrocarbon atoms of 5 to 10 atoms (C5- to C10-framework). Extraction means to selectively solubilize substances or mixtures of substances in order to recover them. The behaviour upon solvation is influenced by the solvent used.
  • aqueous, non-polar, branched or linear chain hydrocarbons are used together with n-hexane for the extraction of the substance or the mixture of substances.
  • the hydrocarbons have a C5 to C10 framework.
  • alcohols and/or a mixture thereof is used for the extraction of the substance or the mixture of substances.
  • alcohols are hydrocarbons having one or more OH-groups at hydrocarbon atoms.
  • alcohols with a framework of 1 to 4 hydrocarbon atoms and/or mixtures thereof are used.
  • methanol or ethanol mixtures thereof are of particular importance.
  • the alcohols used are short chain primary C1 to C4 alcohols and/or mixtures thereof.
  • the alcohols used are methanol and/or ethanol.
  • one or more Phyllanthus constituents or the substances or mixture of substances obtained therefrom are used in combination with other active agents.
  • the Phyllanthus constituents or the substances or mixtures of substances obtained therefrom according to the invention can also be used in combination, i.e. either directly as a mixture, in parallel or subsequently together with other active agents.
  • the other active agents are above, all the pharmaceutical compositions which are known in the therapy of infectious diseases caused by a hepatitis B virus which is resistant to nucleoside analogues.
  • the other active agents are selected from the group consisting of interferon ⁇ , interferon ⁇ , interferon ⁇ and ribavirin.
  • the application is made in the form of an infusion solution, injection solution, a tablet, an ointment, a healing pack, a granular powder, a food additive or in the form of clysters.
  • Phyllanthus constituents or substances or mixtures of substances obtained therefrom can be used in various forms either separately or in combination.
  • the Phyllanthus constituents or the substances or mixtures of substances obtained therefrom can be applied in the form of infusion solutions or injection solutions.
  • a pharmaceutically acceptable solvent is added to the active agents isolated from Phyllanthus constituents or substances or mixtures of substances obtained therefrom in pure or impure form and are introduced into the bloodstream of a patient suffering from an infectious disease which is caused by the infection by hepatitis B viruses which are resistant to nucleoside analogues.
  • infusion solutions and injection solutions are a particular suitable form of application for the treatment.
  • Tablets are a mixture of active agents or adjuvants in the form of a powder or granular powder the shapes of which are regular and always the same (e.g. the shape of a disk, cylinder, oval-, spherical-, rod- or dice-shaped) for a uniform dosage.
  • the active agents can be isolated in pure or impure form from the Phyllanthus constituents of substances or mixtures of substances obtained therefrom according to the invention.
  • the adjuvants are particularly used in connection with the pharmaceutical acceptability and they are used for the preservation and storability of the active agents.
  • An ointment with an active agent which can be present in pure or impure form and which can be produced from the Phyllanthus constituents or the substances or mixtures of substances obtained therefrom according to the invention is a pharmaceutical preparation the form of which can be plastically changed, which comprises the active agent and an ointment base as basis or vehicle.
  • Healing packs in particular, comprise either the Phyllanthus constituents of the invention as such or the substances or mixtures of substances obtained therefrom in pure or impure form and the active agents isolated from the Phyllanthus constituents or the substances or mixtures of substances in pure and impure form in combination with support materials and further active agents.
  • a granular powder is a coarse-grained, graniferous powder mixture containing active agents from the Phyllanthus constituents or the substances or mixtures of substances obtained therefrom according to the invention.
  • a granular powder can also have the form of tablets.
  • the Phyllanthus constituents or the substances or mixtures of substances obtained therefrom according to the invention can also be used as food additives. These are the use of Phyllanthus constituents in the form of foodstuffs and in particular also food additives e.g. in the form of tablets, granular powders or curative teas.
  • the application is carried out in an oral, a topical or a parenteral way.
  • the invention moreover refers to methods for the prevention or treatment of infectious diseases in a mammal which is caused by a hepatitis B virus which is resistant to nucleoside analogues or at the development or progression of which a hepatitis B virus which is resistant to nucleoside analogues participates, wherein one or more Phyllanthus component(s) or substances or mixtures of substances are administered to the mammal.
  • the method according to the invention can, together with the step of administering one or more Phyllanthus constituents or substances or mixtures of substances obtained therefrom, also comprise other steps, e.g. the administration of other therapeutics or additional therapeutic measures.
  • steps e.g. the administration of other therapeutics or additional therapeutic measures.
  • the definitions according to the applications of the invention also apply.
  • the methods of the invention also comprise all embodiments of the application of the invention.
  • the mammal is a human.
  • the invention refers to a method for inhibiting the amplification of a hepatitis B virus which is resistant to nucleoside analogues, wherein one or more Phyllanthus component(s) or substances or mixtures of substances obtained therefrom are contacted with the viruses.
  • the inhibition is carried out ex vivo or in vitro.
  • nucleoside analogues are selected from a group consisting of Lamivudine and Famciclovir.
  • FIG. 1 In HuH7-cells Phyllanthus amarus extract inhibits the “de novo” synthesis of viral DNA in a dose-dependent manner
  • FIG. 1( a ) shows the dose-dependent inhibition of “wild type” HBV-DNA in HuH7 cells.
  • the Phyllanthus amarus extract was tested with concentrations of 0 (negative control) to 1,000 ⁇ g/ml.
  • Lane 1 shows the negative control (no virus was transfected).
  • Lane 2 shows the new synthesis of DNA (virus descendants) in the absence of Phyllanthus amarus extract.
  • Lane 3 shows a positive control (compared to lane 2 half of the HBV-DNA was transfected).
  • Lane 4 shows the molecular weight standard (1 kb ladder).
  • Lanes 5 to 8 show the new formation of HBV-DNA (virus descendants) in the presence of 100 (lane 5), 250 (lane 6), 500 (lane 7) and 1,000 (lane 8) ⁇ g/ml Phyllanthus amarus.
  • FIG. 1( b ) shows the dose-dependent inhibition of the “YMDD (isoleucin) mutant”-HBV-DNA formation in HuH7 cells.
  • the Phyllanthus amarus extract was tested in concentrations of 0 (negative control) to 1,000 ⁇ g/ml.
  • Lane 1 shows the negative control (no virus was transfected).
  • Lane 2 shows the new synthesis of DNA (virus descendants) in the absence of the Phyllantus amarus extract.
  • Lane 3 shows a positive control (compared to lane 2 half of the HBV DNA was transfected).
  • Lane 4 shows the molecular weight standard (1 kb ladder).
  • Lanes 5 to 8 show the new formation of HBV DNA (virus descendants) in the presence of 100 (lane 5), 200 (lane 6), 500 (lane 7) and 1,000 (lane 8) ⁇ g/ml Phyllanthus amarus.
  • the cytotoxicity of the Phyllanthus amarus extract was at first tested in WST1 Assay (Boehringer Mannheim). A cytotoxicity of the extract could thus be excluded. Subsequently, about 10 6 HuH7 cells were plated and cultivated over night. On the next day, these cells were transfected with 15 ⁇ g of the plasmid DNA PHBV1.5 or a plasmid containing the genome of the Lamivudine-resistant YMDD hepatitis B virus mutant by the calcium phosphate method. The transfection efficiency was controlled by co-transfection of 1 ⁇ g of a ⁇ -galactosidase expression plasmid by detection of the ⁇ -galactosidase activity.
  • the transfected HuH7 cells were cultivated for 5 days in a medium containing 100, 250, 500 or 1,000 ⁇ g/ml of the Phyllantus amarus extract. Subsequently, the cells were washed in PBS, collected and homogenised. The homogenised cell suspension was centrifuged in a micro centrifuge at maximum speed. The supernatants were collected and incubated with protein A agarose beads loaded with anti HBC antibodies. After incubation, the beads were washed three times with TNE buffer and were incubated therein for 12 hours at 4° C.
  • the pelleted beads were incubated with DNase (1 U/ml) and RNase (1 U/ ⁇ l) in TNE buffer in the presence of magnesium chloride for 30 minutes at 37° C. After washing the pellet three times with TNE buffer, a treatment with proteinase K (0,5 mg/ml) in the presence of sodium dodecylsulfate (1%) and Sacrosyl for 12 hours at 37° C. so as to release the viral DNA contained in the hepatitis B particles purified by the beads. Subsequently, the DNA was extracted with phenolchlorophorm isoamyl alcohol (25:24:1) and was precipitated in the presence of 10 ⁇ g tRNA.
  • the DNA pellet was then resuspended in 20 ⁇ l TE buffer and was cleaved in a 1% alkaline agarose gel under denaturating conditions. Subsequently, a Southern analysis was carried out wherein the DNA was transferred onto a nylon membrane (Qiabrane Nylon, Qiagen, Germany). In order to detect the viral DNA monomeric DNA was isolated from the plasmid pHBV1.5 and was labelled by a random priming procedure with a radionuclide 32 P. In a subsequent hybridisation, 10 6 cpm/ml of this labelled probe were used. The data obtained show that the Phyllanthus amarus extract significantly inhibits the “de novo” synthesis of viral DNA dependent on the dose of the extract used.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
US10/476,059 2001-04-26 2002-04-26 Use of phyllanthus constituents for treating or preventing infections caused by hepatit Abandoned US20040197426A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/563,540 US7829124B2 (en) 2001-04-26 2006-11-27 Use of Phyllanthus constituents for treating or preventing infections caused by hepatitis B-viruses

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10120627.5 2001-04-26
DE10120627A DE10120627A1 (de) 2001-04-26 2001-04-26 Verwendung von Phyllanthusbestandteilen zur Behandlung oder Prophylaxe von Infekten durch Hepatitis B-Viren
PCT/EP2002/004641 WO2002087600A1 (fr) 2001-04-26 2002-04-26 Utilisation d'elements de phyllanthus pour traiter ou prevenir des infections provoquees par un virus d'hepatite b

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/563,540 Division US7829124B2 (en) 2001-04-26 2006-11-27 Use of Phyllanthus constituents for treating or preventing infections caused by hepatitis B-viruses

Publications (1)

Publication Number Publication Date
US20040197426A1 true US20040197426A1 (en) 2004-10-07

Family

ID=7682913

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/476,059 Abandoned US20040197426A1 (en) 2001-04-26 2002-04-26 Use of phyllanthus constituents for treating or preventing infections caused by hepatit
US11/563,540 Expired - Fee Related US7829124B2 (en) 2001-04-26 2006-11-27 Use of Phyllanthus constituents for treating or preventing infections caused by hepatitis B-viruses

Family Applications After (1)

Application Number Title Priority Date Filing Date
US11/563,540 Expired - Fee Related US7829124B2 (en) 2001-04-26 2006-11-27 Use of Phyllanthus constituents for treating or preventing infections caused by hepatitis B-viruses

Country Status (7)

Country Link
US (2) US20040197426A1 (fr)
EP (1) EP1395270B1 (fr)
JP (1) JP2005500995A (fr)
AU (1) AU2002302580A1 (fr)
CA (1) CA2445373A1 (fr)
DE (1) DE10120627A1 (fr)
WO (1) WO2002087600A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007246429A (ja) * 2006-03-15 2007-09-27 Shiratori Pharmaceutical Co Ltd リパーゼ阻害剤及び飲食品
US20070264359A1 (en) * 2001-04-26 2007-11-15 Micheal Ott Use Of Phyllanthus Constituents For Treating Or Preventing Infections Caused By Hepatitis B-Viruses
CN102600252A (zh) * 2012-04-15 2012-07-25 泰安市中心医院 一种儿童灌肠用退热组合物

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2116253A1 (fr) 2008-05-07 2009-11-11 Phytrix JV, LLC Nouvel extrait de Phyllanthus
EP3954379A1 (fr) * 2020-08-12 2022-02-16 HFM - Hybrid Fusion Medicals, GmbH Compositions comprenant de l'extrait de phyllanthus destinées à être utilisées dans le traitement ou la prévention d'une infection sars-cov-2 et/ou au moins un symptôme de covid-19
CN113735920B (zh) * 2021-09-09 2023-03-21 广西中医药大学 一种氰苷类化合物Menisdaurin F在制备抗乙肝病毒药物组合物中的应用

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US28754A (en) * 1860-06-19 Congress boot
US33275A (en) * 1861-09-10 Improved pipe-joi-nt
US161477A (en) * 1875-03-30 Improvement in curtain-fixtures
US4388457A (en) * 1982-02-11 1983-06-14 University Patents, Inc. Phyllanthostatin compounds
US4673575A (en) * 1985-04-26 1987-06-16 Fox Chase Cancer Center Composition, pharmaceutical preparation and method for treating viral hepatitus
US4937074A (en) * 1988-03-29 1990-06-26 Fox Chase Cancer Center Method of treating retrovirus infection
US5529778A (en) * 1994-09-13 1996-06-25 Rohatgi; Surendra Ayurvedic composition for the prophylaxis and treatment of AIDS, flu, TB and other immuno-deficiencies and the process for preparing the same
US5571441A (en) * 1994-11-01 1996-11-05 The Procter & Gamble Company Nutrient supplement compositions providing physiologic feedback
US5648089A (en) * 1995-07-03 1997-07-15 Shawkat; Tarek Extract solution and herbal mixture for treatment of hepatitis
US5854233A (en) * 1993-09-08 1998-12-29 Pharmacy And Therapeutic Advisory Consultancy Ltd. Method of treating liver disease and like indications with vasodilating agents
US6136316A (en) * 1996-04-17 2000-10-24 Dabur Research Foundation Hepatoprotective compositions and composition for treatment of conditions related to hepatitis B and E infection
US6258831B1 (en) * 1999-03-31 2001-07-10 The Procter & Gamble Company Viral treatment
US20020054921A1 (en) * 2000-06-20 2002-05-09 Christoph Von Keudell Use of phyllanthus components for the treatment or prophylaxis of infections triggered by flavivirdae
US6586015B1 (en) * 1999-04-29 2003-07-01 Phytrix Ag Use of Phyllanthus for treating chronic inflammatory and fibrotic processes

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2175129A (en) 1985-04-26 1986-11-19 Philips Nv Radiographic image intensifier
CA2001898A1 (fr) 1988-10-31 1990-04-30 Kuo-Hsiung Lee Inhibition de retrovirus humains
GB2331460B (en) * 1996-08-16 1999-12-22 Hepaguard Co Ltd Pharmaceutical composition for the treatment of hepatitis B comprising extract of phyllanthus ussuriensis and/or phyllanthus urinaria
US6258931B1 (en) * 1998-08-19 2001-07-10 University Of Florida Research Foundation, Inc. Deoxyhypusine reagent and peptides
WO2000056347A1 (fr) * 1999-03-24 2000-09-28 Southern Petrochemical Industries Corporation Limited Fraction enrichie preparee a partir de phyllanthus amarus pour le traitement de l'hepatite et preparation de cette fraction
CA2334754A1 (fr) * 1999-04-12 2000-10-19 University Of Madras Formulation pharmaceutique utile pour le traitement de l'hepatite b, de l'hepatite c et d'autres infections virales du foie ; procede de preparation de cette formulation pharmaceutique
DE10120627A1 (de) * 2001-04-26 2002-10-31 Cmi Ag Verwendung von Phyllanthusbestandteilen zur Behandlung oder Prophylaxe von Infekten durch Hepatitis B-Viren

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US28754A (en) * 1860-06-19 Congress boot
US33275A (en) * 1861-09-10 Improved pipe-joi-nt
US161477A (en) * 1875-03-30 Improvement in curtain-fixtures
US4388457A (en) * 1982-02-11 1983-06-14 University Patents, Inc. Phyllanthostatin compounds
US4673575A (en) * 1985-04-26 1987-06-16 Fox Chase Cancer Center Composition, pharmaceutical preparation and method for treating viral hepatitus
US4937074A (en) * 1988-03-29 1990-06-26 Fox Chase Cancer Center Method of treating retrovirus infection
US5854233A (en) * 1993-09-08 1998-12-29 Pharmacy And Therapeutic Advisory Consultancy Ltd. Method of treating liver disease and like indications with vasodilating agents
US5529778A (en) * 1994-09-13 1996-06-25 Rohatgi; Surendra Ayurvedic composition for the prophylaxis and treatment of AIDS, flu, TB and other immuno-deficiencies and the process for preparing the same
US5571441A (en) * 1994-11-01 1996-11-05 The Procter & Gamble Company Nutrient supplement compositions providing physiologic feedback
US5648089A (en) * 1995-07-03 1997-07-15 Shawkat; Tarek Extract solution and herbal mixture for treatment of hepatitis
US6136316A (en) * 1996-04-17 2000-10-24 Dabur Research Foundation Hepatoprotective compositions and composition for treatment of conditions related to hepatitis B and E infection
US6258831B1 (en) * 1999-03-31 2001-07-10 The Procter & Gamble Company Viral treatment
US6586015B1 (en) * 1999-04-29 2003-07-01 Phytrix Ag Use of Phyllanthus for treating chronic inflammatory and fibrotic processes
US20020054921A1 (en) * 2000-06-20 2002-05-09 Christoph Von Keudell Use of phyllanthus components for the treatment or prophylaxis of infections triggered by flavivirdae

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070264359A1 (en) * 2001-04-26 2007-11-15 Micheal Ott Use Of Phyllanthus Constituents For Treating Or Preventing Infections Caused By Hepatitis B-Viruses
JP2007246429A (ja) * 2006-03-15 2007-09-27 Shiratori Pharmaceutical Co Ltd リパーゼ阻害剤及び飲食品
CN102600252A (zh) * 2012-04-15 2012-07-25 泰安市中心医院 一种儿童灌肠用退热组合物

Also Published As

Publication number Publication date
JP2005500995A (ja) 2005-01-13
CA2445373A1 (fr) 2002-11-07
WO2002087600A1 (fr) 2002-11-07
EP1395270B1 (fr) 2014-07-23
EP1395270A1 (fr) 2004-03-10
US20070264359A1 (en) 2007-11-15
WO2002087600A8 (fr) 2002-12-12
US7829124B2 (en) 2010-11-09
DE10120627A1 (de) 2002-10-31
AU2002302580A1 (en) 2002-11-11

Similar Documents

Publication Publication Date Title
US7829124B2 (en) Use of Phyllanthus constituents for treating or preventing infections caused by hepatitis B-viruses
KR20000023648A (ko) 식물 추출물로부터의 항바이러스제 및 바이러스 감염의 치료를 위한 사용
AU711019B2 (en) Pharmaceutical compositions containing parthenium integrifolium or parts thereof or an extract or component thereof, the use of such plant material for preparing certain medicines, and a method of preparing an extract of parthenium integrifolium
JP2012021022A (ja) 草本植物である、ハマウツボ科の全寄生植物［ｃｉｓｔａｎｃｈｅｔｕｂｕｌｏｓａ（ｓｃｈｅｎｋ．）ｗｉｇｈｔ］から抽出されるフェニルエタノイド配糖体を含む医薬調製物、これの製造方法およびこれの使用
JP4556009B2 (ja) 抗炎症剤、アレルギー性疾患予防又は改善剤及び機能性食品
US20070134711A1 (en) Compositions of eleutherosides capable of modulating protein expresion
CN106822152B (zh) 一种药物组合物及其应用
CN108379495B (zh) 高良姜提取物在制备预防和/或治疗非酒精性脂肪肝制剂中的用途
KR20010099494A (ko) 큰등골짚신나물로부터 분리한 ｂ형 간염바이러스 표면항원억제물질과 그 추출방법 및 용도
KR20040018733A (ko) 고들빼기 추출물을 함유한 바이러스성 간질환 치료용 조성물
KR20090003632A (ko) 항염증 활성을 갖는 야국 추출물을 포함하는 조성물
KR20080101344A (ko) 탄닌 함유 해동피 추출물을 유효성분으로 하는 소염 진통제조성물
CN110536690B (zh) 用于预防或治疗丙型肝炎病毒感染疾病的药学组合物
WO2003074000A2 (fr) Eleutherosides utilises comme adjuvant pour des vaccins et modulation immune
JP3010258B2 (ja) 抗ｈｉｖ剤
JP2004262929A (ja) α−グルコシダーゼ阻害剤
JPH10251154A (ja) 肝炎抑制組成物
KR100370501B1 (ko) 금은화추출물을포함하는비형간염치료제
JPH0987193A (ja) ショウガ科植物の抽出物を含有する抗ヒト免疫不全ウイルス剤
US20020031563A1 (en) Method of inhibiting tumor necrosis factor
Chinou Assessment report on Olea europaea L., folium
JPH11310527A (ja) 医薬組成物
KR20240094160A (ko) 델타형 SARS-CoV-2 변이체의 감염을 억제하는 지유추출 조성물
KR20040018730A (ko) 마과, 씀바귀 및 고들빼기의 추출물을 함유한 복합생약바이러스성 간질환 치료용 조성물
JP5080709B2 (ja) 抗高脂血症組成物及びその製造方法

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION